Q2 2020 Earnings Estimate for Halozyme Therapeutics, Inc. (HALO) Issued By Piper Jaffray Companies

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Piper Jaffray Companies issued their Q2 2020 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a note issued to investors on Tuesday, May 7th. Piper Jaffray Companies analyst J. Catanzaro forecasts that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter. Piper Jaffray Companies also issued estimates for Halozyme Therapeutics’ FY2021 earnings at $0.36 EPS and FY2022 earnings at $1.30 EPS.

Several other equities analysts have also commented on HALO. Zacks Investment Research lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 11th. BidaskClub raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Halozyme Therapeutics in a research report on Monday, February 4th. JMP Securities reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, February 27th. Finally, ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $20.17.

Shares of Halozyme Therapeutics stock opened at $16.22 on Thursday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.07. Halozyme Therapeutics has a 52 week low of $13.24 and a 52 week high of $19.96.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.01 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The firm had revenue of $56.95 million during the quarter, compared to analyst estimates of $67.80 million. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. Halozyme Therapeutics’s revenue was up 84.3% on a year-over-year basis. During the same period last year, the firm posted ($0.19) EPS.

A number of institutional investors and hedge funds have recently bought and sold shares of HALO. JPMorgan Chase & Co. raised its position in Halozyme Therapeutics by 12.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,601,604 shares of the biopharmaceutical company’s stock worth $65,441,000 after buying an additional 400,008 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 24.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 802,171 shares of the biopharmaceutical company’s stock worth $14,575,000 after buying an additional 158,349 shares during the last quarter. Teachers Advisors LLC raised its position in Halozyme Therapeutics by 1.1% during the 3rd quarter. Teachers Advisors LLC now owns 322,091 shares of the biopharmaceutical company’s stock worth $5,852,000 after buying an additional 3,638 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in Halozyme Therapeutics by 2.6% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 538,680 shares of the biopharmaceutical company’s stock worth $9,788,000 after buying an additional 13,651 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Halozyme Therapeutics by 28.1% during the 3rd quarter. Legal & General Group Plc now owns 54,981 shares of the biopharmaceutical company’s stock worth $999,000 after buying an additional 12,044 shares during the last quarter. 83.33% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

There is no company description available for Halozyme Therapeutics Inc

Read More: Trade Deficit

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.